Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease | Zendy

Yael Segev | Zendy; R. Eshet | Zendy; I. Rivkis | Zendy; C. S. Hayat | Zendy; Leonid Kachko | Zendy; Moshe Phillip | Zendy; Danny Landau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease

Author(s) -

Yael Segev,

R. Eshet,

I. Rivkis,

C. S. Hayat,

Leonid Kachko,

Moshe Phillip,

Danny Landau

Publication year - 2004

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfh528

Subject(s) - medicine , endocrinology , enalapril , diabetic nephropathy , diabetes mellitus , somatostatin , kidney disease , type 2 diabetes , ace inhibitor , octreotide , albuminuria , angiotensin converting enzyme , blood pressure

The growth hormone (GH)-insulin-like growth factor (IGF)-SST (SST) axis is involved in diabetic nephropathy (DN). We have recently shown a beneficial effect on diabetic kidney disease markers by the use of a novel somatostatin (SST) analogue (PTR-3173) (S). The purpose of this study is to compare the effects of S with a previously used SST analogue (octreotide) and an ACE inhibitor (ACEi), a standard of care in DN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research